Latest studies
- RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
Metastatic Non-small Cell Lung CancerSwitzerland - Enrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
This study is gathering information worldwide on a rare condition called Congenital Portosystemic Shunt (CPSS). It aims to better understand how CPSS affects people, why some develop serious problems, and how best to manage it. This will help improve care for those with CPSS.
Congenital Portosystemic ShuntCPSS (Congenital Portosystemic Shunt)Switzerland - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaSwitzerland - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisSwitzerland - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia ASwitzerland - Active not recruitingPHASE3
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
This study compares two treatments for a type of slow-growing lymphoma called Splenic Marginal Zone Lymphoma (SMZL). It looks at whether a combination of two drugs, rituximab and zanubrutinib, works better and is as safe as rituximab alone for patients needing their first treatment.
Splenic Marginal Zone LymphomaSwitzerland - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaSwitzerland - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerSwitzerland - RecruitingPHASE2, PHASE3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
This study is testing a new medicine, efgartigimod PH20 SC, for children aged 2 to 17 with a muscle weakness condition called generalised Myasthenia Gravis. We want to find the best dose and make sure it's safe. Participants will get injections and be monitored.
Generalized Myasthenia GravisSwitzerland - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionSwitzerland - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisSwitzerland - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Switzerland - RecruitingPHASE4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
This study looks at how well a medicine called pegcetacoplan works and if it's safe for people in the UK with rare kidney diseases like C3G or IC-MPGN. It uses real-life information from patients to help doctors make better decisions about treatment.
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Switzerland - Active not recruitingPHASE3
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
This study looks at the long-term safety of a new medicine called Nemolizumab for people with Prurigo Nodularis. It's for those who have already tried Nemolizumab in a previous study for this skin condition.
Prurigo NodularisSwitzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerSwitzerland - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Duvakitug for people with Crohn's disease that isn't well controlled. It compares Duvakitug to a dummy medicine to see if it's safe and effective in improving symptoms for those with moderately to severely active Crohn's.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
Neoplasms, LungSwitzerland - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
Ulcerative ColitisSwitzerland - RecruitingPHASE3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart, against the usual treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It's for adults already receiving IVIg to see if riliprubart works safely and effectively to manage their condition.
Chronic Inflammatory Demyelinating PolyneuropathySwitzerland - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerSwitzerland - RecruitingPHASE2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
This study is looking at a new medicine called ALN-APP for a condition called Cerebral Amyloid Angiopathy (CAA). It aims to see how well ALN-APP works to slow down CAA and if it's safe. Participants will either receive the new medicine or a dummy treatment.
Cerebral Amyloid AngiopathySwitzerland - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
Renal Cell CarcinomaSwitzerland - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Switzerland - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerSwitzerland - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Switzerland - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
Carcinoma, Non-Small-Cell LungSwitzerland - RecruitingPHASE4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
This study looks at whether blood-thinning medicines (anticoagulants) can prevent strokes and other heart-related problems in people who have had temporary episodes of an irregular heartbeat called atrial fibrillation (AF) during stressful times like surgery or serious illness.
StrokeAtrial FibrillationSwitzerland - Active not recruitingPHASE3
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
This study is testing a new drug, elafibranor, for people with a liver condition called Primary Biliary Cholangitis (PBC). It aims to see if the drug can improve liver health and reduce symptoms like itching and tiredness compared to a dummy treatment.
Primary Biliary CirrhosisSwitzerland - RecruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast NeoplasmsEsophageal Squamous Cell CarcinomaSwitzerland - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerSwitzerland - Not yet recruitingNA
Effectiveness of an Interprofessional Approach to the Treatment of Spasticity With Botulinum Toxin & Non-pharmacological Therapies
This study looks at how well a team approach works for treating muscle stiffness (spasticity) using Botox injections and other therapies. Researchers want to see if combining these treatments helps people reach their personal goals and improve their daily lives.
SpasticitySwitzerland - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
HER2 Positive Breast CancerSwitzerland - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenSwitzerland - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerSwitzerland - Enrolling by invitationPHASE3
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study looks at the long-term safety and effects of a new drug called litifilimab for adults with certain types of lupus affecting the skin. It's for people who were in an earlier study and whose lupus didn't improve with usual treatments.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusSwitzerland - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
Non-Small Cell Lung CancerSwitzerland - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerSwitzerland - RecruitingNA
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
This study looks at whether a procedure to close off a part of the heart called the left atrial appendage (LAA) in addition to blood thinners can better prevent strokes in people with atrial fibrillation who have already had a stroke despite being on blood thinners.
Ischemic StrokeAtrial FibrillationSwitzerland - RecruitingPHASE3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study looks at a long-term eye implant to treat 'wet' age-related macular degeneration (nAMD). It checks the safety of the implant and how well it works over time in people who have been in previous studies. It also explores ways to manage potential side effects.
Neovascular Age-Related Macular DegenerationSwitzerland - Active not recruitingPHASE2, PHASE3
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This study is testing a new drug called imetelstat for certain types of Myelodysplastic Syndromes (MDS). It aims to see if the drug can help reduce the need for blood transfusions and is safe to use for people whose current treatment hasn't worked.
Myelodysplastic SyndromesSwitzerland - Active not recruitingPHASE1, PHASE2
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
This study is testing a new medicine, Anvumetostat, for people with advanced cancers that are missing a specific gene called MTAP. Researchers want to find the safest dose, see how well it works, and understand its side effects, sometimes given with another cancer drug called Docetaxel.
Advanced MTAP-null Solid TumorsSwitzerland - RecruitingPHASE2, PHASE3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
This study is looking for better treatments for a common eye condition called wet macular degeneration. Researchers want to see if a new medicine, tiespectus, works as well as an existing treatment, aflibercept. It's for people recently diagnosed with this condition.
Macular DegenerationAge-Related Macular DegenerationChoroidal NeovascularizationWet Macular DegenerationSwitzerland - Active not recruitingPHASE3
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study is looking at a new medicine called Niraparib to see if it can help women with advanced ovarian cancer stay well for longer after their first round of chemotherapy. It’s comparing Niraparib to a dummy drug (placebo).
Ovarian NeoplasmsSwitzerland - Active not recruitingPHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is looking at a new combination of medicines, Dato-DXd and pembrolizumab, for advanced lung cancer. It compares this combination to pembrolizumab alone to see if it's more effective and safe for people whose cancer hasn't spread and who haven't had other treatments yet.
Metastatic Non Small Cell Lung CancerSwitzerland - RecruitingPHASE2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
This study is testing a new cell therapy called rapcabtagene autoleucel for severe lupus (SLE) or lupus affecting the kidneys (lupus nephritis). It aims to see how well it works and if it's safe for people whose current treatments aren't effective.
Lupus Erythematosus, SystemicLupus NephritisSwitzerland - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
Diffuse Large B-Cell LymphomaSwitzerland - Active not recruitingPHASE2, PHASE3
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
This study is looking at a new drug, Navlimetostat, combined with standard treatment (Nab-paclitaxel and Gemcitabine) for pancreatic cancer that has spread. It's for people whose cancer has a specific genetic change called MTAP deletion, which the new drug targets.
Pancreatic Ductal AdenocarcinomaSwitzerland